What is circulating cell-free DNA, and how can it change healthcare? Discover how cfDNA offers non-invasive insights for cancer, prenatal care, and organ transplants.

Study findings suggested that assessing ctDNA levels was as good or better at predicting recurrence than experimental tests that examine a tumor itself.

Nidadavolu, L. S., et al. (2023) Associations between circulating cell-free mitochondrial DNA, inflammatory markers, and cognitive and physical outcomes in community dwelling older adults.

Fortunately, circulating tumor DNA (ctDNA) can be detected in peripheral blood cell–free DNA (cfDNA) from most patients with progressive disease. 1 - 4 Numerous research, industry, and commercial ...

A ctDNA test may be sensitive enough to assess tumor burden and help guide treatment plans for people with locally advanced or metastatic colorectal cancer.

Cell-Free DNA Drives Liquid Biopsy Testing Capturing and identifying circulating DNA could hold the key to rapid, minimally invasive, disease diagnostics—ultimately improving clinical decision ...

Circulating tumor DNA can be readily detected in patients with central nervous system lymphoma and may be a strong clinical biomarker for risk stratification, outcomes prediction and surgery-free ...

The method, called GETMap, could be used in prenatal screening, to monitor organ transplant rejection, or test for cancers that are concealed in the body. "Analysis of circulating free DNA has ...

To characterize the patient population utilizing circulating cell-free fetal DNA (ccffDNA) testing at a large academic center and evaluate trends in the performance of invasive diagnostic procedures.

Circulating tumor DNA — which is observed via blood test — may be helpful in determining which patients with kidney cancer need more intense treatment and who can have their therapies deescalated.

Colorectal cancer screening remains inadequate in France, but DNA tests could enable screening through a simple blood test or stool analysis.